Weekly Tech+Bio Highlights #71: More China Deals

DeepMind's new deep learning model lands in Nature, Big Pharma's $18B+ plans for China, FDA clears first epigenetic reprogramming trial

Last week of January saw some more deals between Western pharma and China, with the more notable being AstraZeneca’s $15B China plan for small molecules/radiopharma, and a $18.5B deal with CSPC Pharmaceutical Group to develop long-acting obesity/diabetes drugs, not long after their summer $5.3B AI drug discovery deal.

On the tech side, DeepMind’s AlphaGe…